Sarepta's Q3 2025 revenues fell 15% to $399.4 million due to reduced ELEVIDYS sales. The company posted a net loss of $179.9 million and a non-GAAP loss of $12.9 million. PMO therapies and gene therapy ELEVIDYS contributed to the revenue mix.
Q3 2025 revenue declined to $399.4 million from $467.2 million in Q3 2024.
Reported net loss of $179.9 million; adjusted non-GAAP net loss was $12.9 million.
ELEVIDYS revenue decreased $49.5 million due to shipment pause to non-ambulatory patients.
Completed ESSENCE confirmatory study for PMO therapies AMONDYS 45 and VYONDYS 53.
Sarepta plans to engage with the FDA on potential label updates and paths to full approval for its PMO therapies, while focusing on expanding its siRNA pipeline and restoring ELEVIDYS momentum.
Analyze how earnings announcements historically affect stock price performance